Concepedia

Fatima Bhayat

FB

Statistics

Publications

11

Citations

594

H-Index

10

Active since

2009

Affiliations

Takeda (United States)(Current)

Takeda (United Kingdom)

National Patient Safety Foundation

Icahn School of Medicine at Mount Sinai

Deerfield (United States)

Fatima Bhayat is an author at Takeda (United States) specializing in inflammatory bowel disease, vedolizumab therapy, and medicine.

Publications per year

2009–2019

11

Publications

11

Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease

Uma Mahadevan, Séverine Vermeire, Karen Lasch et al. · Alimentary Pharmacology & Therapeutics · 2017 · 128 citations · Full text

, , +15

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

Siew C. Ng, Ida Hilmi, Aimee Blake et al. · Inflammatory Bowel Diseases · 2018 · 95 citations · Full text

, , +13

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials

Brian G. Feagan, William J. Sandborn, Jean‐Frédéric Colombel et al. · Journal of Crohn s and Colitis · 2018 · 80 citations · Full text

, , +15

The incidence of and mortality from leukaemias in the UK: a general population-based study

Fatima Bhayat, Emma Das‐Gupta, Chris Smith et al. · BMC Cancer · 2009 · 73 citations · Full text

, , +17

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-marketing Data

Russell D. Cohen, Fatima Bhayat, Aimee Blake et al. · Journal of Crohn s and Colitis · 2019 · 70 citations

, , +16

1–5 of 11